Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same
The present invention is directed in part to pharmaceutical compositions for storage and administration comprising a) a HER2/neu antibody (“margetuximab”), b) buffering agents, and c) stabilizers, wherein said margetuximab is stable. The invention in part provides, containers and kits comprising such pharmaceutical compositions. The invention is directed in part to the use of such pharmaceutical compositions, containers, and kits containing margetuximab in the treatment of HER2/neu-positive cancer (i.e., a cancer that expresses HER2), including breast cancer or gastric cancer or GEJ cancer.
1 - 85 . (canceled)
86 . A method of treating cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a margetuximab-comprising pharmaceutical composition to said subject; said pharmaceutical composition comprising a concentration of margetuximab from about 20 mg/mL to about 100 mg/mL, a sodium phosphate monohydrate buffer, a sodium phosphate dibasic heptahydrate buffer, sodium chloride, L-arginine hydrochloride and sucrose as stabilizers, polysorbate 80 (“PS80”) and water, wherein the margetuximab is stable.
87 . The method of claim 86 , wherein said method comprises:
(a) diluting the pharmaceutical composition in a container in 0.9% sodium chloride to obtain a dosing solution;
(b) inverting the container to mix the diluted solution; and
(c) attaching the container containing the dosing solution to a device for administration to the subject.
88 . The method of claim 87 , wherein said container is an IV bag containing 0.9% sodium chloride.
89 . The method of claim 87 , wherein said dosing solution maintains monomeric purity of said margetuximab for about 24 hours at 25° C. or for about 24 hours at 2-8° C.
90 . The method of claim 86 , wherein said administration is by intravenous (IV) infusion for at least 30 minutes.
91 . The method of claim 86 , wherein said pharmaceutical composition is diluted to obtain a dosing solution that comprises about 15 mg/kg of margetuximab.
92 . The method of claim 87 , wherein an initial administration of said dosing solution is administered as an IV infusion over about 120 minutes.
93 . The method of claim 92 , wherein subsequent administrations of the dosing solution are administered as an IV infusion over about 60 minutes every 3 weeks.
94 . The method of claim 92 , wherein subsequent administrations of the dosing solution are administered as an IV infusion over about 30 minutes every 3 weeks.
95 . The method of claim 86 , wherein said cancer is a HER2/neu-positive (HER2 + ) cancer.
96 . The method of claim 86 , wherein said cancer is selected from the group consisting of: an adrenal gland cancer, anal cancer, AIDS-associated cancer, alveolar soft part sarcoma, bile duct cancer, a cholangiocarcinoma bile duct cancer, bladder cancer, bone cancer, brain and spinal cord cancer, breast cancer, metastatic breast cancer, carotid body tumor, cervical cancer, an HPV-related cervical cancer, chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, desmoplastic small round cell tumor, ependymoma, endometrial cancer, Ewing's sarcoma, extraskeletal myxoid chondrosarcoma, fibrogenesis imperfecta ossium, fibrous dysplasia of the bone, gallbladder or bile duct cancer, gastric cancer, gastroesophageal junction (GEJ) cancer, gestational trophoblastic disease, germ cell tumor, head and neck cancer, islet cell tumor, Kaposi's Sarcoma, kidney cancer, leukemia, liposarcoma/malignant lipomatous tumor, liver cancer, a hepatocellular carcinoma liver cancer (HCC), lymphoma, a non-Hodgkin's lymphoma (NHL), lung cancer, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), medulloblastoma, melanoma, meningioma, Merkel cell carcinoma, multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, neuroendocrine tumors, ovarian cancer, pancreatic cancer, papillary thyroid carcinoma, parathyroid tumor, pediatric cancer, peripheral nerve sheath tumor, pheochromocytoma, pituitary tumor, prostate cancer, posterious uveal melanoma, renal metastatic cancer, rhabdoid tumor, rhabdomyosarcoma, sarcoma, skin cancer, soft-tissue sarcoma, squamous cell cancer, a squamous cell carcinoma head and neck cancer (SCCHN), stomach cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid cancer, and uterine cancer.
97 . The method of claim 86 , wherein said cancer is gastric cancer, or GEJ cancer.
98 . The method of claim 86 , wherein said cancer is breast cancer or metastatic breast cancer.